Insider Buying: Hvivo PLC (HVO) Insider Buys 17,863 Shares of Stock
Hvivo PLC (LON:HVO) insider Jaime Ellertson bought 17,863 shares of the business’s stock in a transaction on Wednesday, October 4th. The shares were bought at an average cost of GBX 75 ($0.99) per share, for a total transaction of £13,397.25 ($17,770.59).
Jaime Ellertson also recently made the following trade(s):
- On Friday, July 7th, Jaime Ellertson bought 16,888 shares of Hvivo PLC stock. The shares were bought at an average cost of GBX 89 ($1.18) per share, for a total transaction of £15,030.32 ($19,936.76).
Hvivo PLC (LON HVO) opened at 67.50 on Thursday. The stock has a 50 day moving average price of GBX 75.69 and a 200-day moving average price of GBX 98.37. The firm’s market capitalization is GBX 52.73 million. Hvivo PLC has a 52 week low of GBX 67.50 and a 52 week high of GBX 239.75.
Hvivo PLC (LON:HVO) last posted its earnings results on Thursday, September 21st. The company reported GBX (9.90) (($0.13)) earnings per share (EPS) for the quarter. The business had revenue of GBX 392 million during the quarter. Hvivo PLC had a negative return on equity of 32.75% and a negative net margin of 73.08%. Analysts anticipate that Hvivo PLC will post ($17.00) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/05/insider-buying-hvivo-plc-hvo-insider-buys-17863-shares-of-stock.html.
Separately, Numis Securities Ltd downgraded Hvivo PLC to a “hold” rating and set a GBX 80 ($1.06) target price on the stock. in a report on Thursday, September 21st.
About Hvivo PLC
hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold.
Receive News & Ratings for Hvivo PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo PLC and related companies with MarketBeat.com's FREE daily email newsletter.